Tracon Pharmaceuticals Inc (TCON)

Overview

TRACON Pharmaceuticals, Inc. is a biopharmaceutical company rooted in the United States, primarily focusing on the innovation and commercialization of novel targeted therapeutics for cancer treatment. Having undergone a name change from Lexington Pharmaceuticals, Inc. to TRACON Pharmaceuticals, Inc. in March 2005, the company was established in 2004. Its headquarters are located in San Diego, California. TRACON is engaged in collaboration and license agreements with prominent industry partners such as 3D Medicines Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and I-Mab Biopharma to advance its pipeline of drugs. Moreover, a cooperative research and development agreement with the National Cancer Institute underscores its deep involvement in pioneering cancer treatments.

Products and Services

• Envafolimab (KN035): Positioned as a novel therapeutic for the treatment of refractory soft tissue sarcoma, envafolimab, a PD-L1 single-domain antibody, showcases TRACON's dedication to addressing unmet medical needs in oncology. Its development is underpinned by collaboration agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd.
• YH001: A testament to TRACON's innovative efforts in cancer therapy, YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody, is currently undergoing Phase I clinical trials. Targeting various cancer indications, it represents another facet of the company’s diverse oncological portfolio.
• TRC102: As a small molecule in advanced clinical evaluation, TRC102 is exploring therapeutic avenues across a spectrum of cancers, including mesothelioma, solid tumors, lung cancer, and glioblastoma. Its current stage involves Phase II clinical trials for mesothelioma and Phase I trials for the aforementioned cancers, exemplifying TRACON’s commitment to broadening options for cancer treatment.
• TJ004309: In the realm of immuno-oncology, TJ004309 stands out as a CD73 antibody, presently in Phase I clinical development aimed at the treatment of solid tumors. This development efforts underscore the company's focus on harnessing the immune system to combat cancer, with cooperative development spearheaded alongside I-Mab Biopharma.
• Bispecific Antibodies: The preclinical stage bispecific antibodies represent the cutting-edge frontier of TRACON Pharmaceuticals' research endeavors. These innovative molecules are designed to engage multiple therapeutic targets simultaneously, reflecting the company’s forward-thinking approach to cancer treatment.